sodium-morrhuate and Hemangioma

To evaluate the efficacy and security of modified and traditional sclerotherapy in treating angioma in ENT.. For the Angioma of derma and hypodermis (naso face, auricles, neck) 56 cases and 82 cases of mucosa and hypomucosa (the cavities of nose, throat and mouth) were randomized divided into 2 groups each.: The 5% Sodium Morrhate + Triamcinolone Acetonide (The Modified Sclerotherapy n = 28, n = 41) and only 5% Sodium Morrhate (Traditional Sclerotherapy n = 28, n = 41) were respectively injected into bodies of Angioma, as one time a week for 2-6 weeks, on average 19 days.. The rates of cure and effective for Modified and Traditional Sclerotherapies were 84.1%, 65.2% and 91.3%, 85.5% respectively. There is a significant in statistics for effective rates and there is a notable difference in cured rates between the two therapies. It shows that Modified Sclerotherapy has an obvious advantage (P < 0.05). Although the efficacy is similar between the two therapies for angioma of mucosa and hypomucosa, the difference has a significant in efficacy for angioma of derma and hypoderma between the two therapies (P < 0.05) and the side-effects were very slight for Modified Sclerotherapy.. There is a more prominent efficacy and security for Modified Sclerotherapy than Traditional Sclerotherapy.

Topics: Adolescent; Adult; Child; Child, Preschool; Drug Therapy, Combination; Female; Hemangioma; Humans; Infant; Male; Middle Aged; Otorhinolaryngologic Neoplasms; Sclerotherapy; Sodium Morrhuate; Triamcinolone Acetonide

Topics: Hemangioma; Humans; Necrosis; Sclerosing Solutions; Sclerotherapy; Sodium Morrhuate

Hemangioma is a common benign tumor affecting infants. In this study, we prepared sodium morrhuate immunoliposomes through encapsulation of sodium morrhuate with liposomes coupled with an anti-VEGFR2/KDR antibody and examined its effect on the biology of human hemangioma endothelial cells (HECs). It was found that compared to the liposomal sodium morrhuate group, treatment with sodium morrhuate immunoliposomes facilitated cell detachment and apoptotic death. Confocal microscopy analysis revealed that sodium morrhuate immunoliposomes had a higher binding activity to HECs than liposomal sodium morrhuate. Apoptosis analysis further demonstrated that treatment with liposomal sodium morrhuate or sodium morrhuate immunoliposomes significantly induced apoptosis in HECs, compared to the control group. Western blot analysis revealed an induction of caspase-3 and caspase-9 levels and reduction of caspase-8 and Bcl-2 levels in HECs treated with liposomal sodium morrhuate or sodium morrhuate immunoliposomes. Taken together, these results indicate that sodium morrhuate immunoliposomes have an increased capacity to target HECs and promote mitochondrial apoptosis. Therefore, sodium morrhuate immunoliposomes may represent a promising agent in the treatment of hemangiomas.

Topics: Antibodies, Monoclonal; Biological Assay; Cell Death; Cell Shape; Endothelial Cells; Hemangioma; Humans; Liposomes; Sodium Morrhuate; Vascular Endothelial Growth Factor Receptor-2

Topics: Hand; Hemangioma; Humans; Infant; Male; Necrosis; Sclerosing Solutions; Sclerotherapy; Skin Neoplasms; Sodium Morrhuate

Hemangioma is the most common benign tumor of infancy. The aim of this study is to evaluate the biological effects of sodium morrhuate (SM) and its liposomal formulation on infantile hemangioma endothelial cells (IHECs). Morphological analysis revealed that exposure to liposomal sodium morrhuate (LSM) preferentially caused apoptotic death in IHECs, manifested as shrunken configuration and formation of apoptotic bodies. In contrast, necrotic death was prominent in IHECs treated with an equal concentration of SM. By means of proteomic analysis and confirmation experiments, we revealed that the apoptosis-inducing effects of LSM were associated with an upregulation of a set of genes involved in mitochondrial death pathway, including apoptosis-inducing factor, cytochrome c1, caspase-8, and lamin B1. In conclusion, our data highlight the proapoptotic activity of LSM in IHECs through the mitochondrial apoptotic pathway and may provide a promising avenue to treat hemangiomas of infancy.

Topics: Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Caspase 8; Cell Shape; Cytochromes c1; Drug Compounding; Endothelial Cells; Gene Expression; Hemangioma; Humans; Infant; Lamin Type B; Liposomes; Mitochondria; Mitochondrial Proteins; Proteome; Proteomics; Sodium Morrhuate; Tumor Cells, Cultured

To explore the method of preparing immunolipo-sodium morrhuate and evaluate its effect on human hemangioma endothelial cells in vitro.. Using SPDP((N-Succinimidyl-3-(2-pyridyldithio)) propionate) as cross-linker, anti-VEGFR2/KDR monoclone antibody was combined to the liposome surface to prepare immunolipo-sodium morrhuate by extruding method, and then its effect on human hemangioma endothelial cells in vitro was observed by laser scanning confocal microscope, inverted microscope, Gimsa staining, transmission electron microscope, MTT and flow cytometry.. The average diameter of the immunoliposome was 122.9 nm, which had a very good stability when compared with normal liposome, it had stronger and faster combining ability, its potential to induce apoptosis was much more prominent, and its toxic effect on human hemangioma endothelial cells was gentle, which was similar to normal liposome.. We have prepared immunolipo-sodium morrhuate successfully, which has very good specific initiative targetting ability in vitro and can induce pervasive apoptosis of human hemangioma endothelial cells.

Topics: Apoptosis; Endothelial Cells; Hemangioma; Humans; In Vitro Techniques; Liposomes; Sclerosing Solutions; Sodium Morrhuate

Of the congenital vascular abnormalities, venous malformations receive little attention and essentially no discussion of treatment. The author describes a 30-year experience with sclerotherapy, which was used for 34 venous malformations. In some cases, these lesions are localized and can be excised, but all the patients in this series had such extensive involvement of adjacent organ systems that no other treatment than sclerotherapy was tenable. Five patients had Klippel-Trenaunay Syndrome, five had head and neck involvement, two had involvement of the entire left side and the remainder had other areas affected. Sodium morrhuate, ethanolamine, sotradecol, and absolute ethyl alcohol were the sclerosing agents used. A butterfly needle was inserted into an anomalous vein, and a three-way stopcock connected to saline and the sclerosing solution was used to ensure intraluminal injection. When rapid runoff into normal venous tributaries could be a concern, a venogram on the operating table preceded injection of the sclerosing solution. Small lesions required only one treatment; widespread bulky lesions required more than 30 injections. The volume of sclerosing solution varied from 5 to 90 mL per injection course. Because of pain, general anesthesia and an overnight hospital stay were necessary. Patients with pharyngeal and/or laryngeal involvement required preliminary tracheostomy or endotracheal ventilatory support for 3 days. Complications included skin necrosis, transient nerve palsy, hemoglobinuria, and one case of anaphylaxis. Repeated aggressive treatment was required for the very large malformations because recanalization occurred. All the patients have been very satisfied with the results.

Topics: Adolescent; Adult; Child; Child, Preschool; Female; Hemangioma; Humans; Male; Phlebography; Sclerotherapy; Sodium Morrhuate; Thrombophlebitis; Thrombosis; Veins

Topics: Angiography, Digital Subtraction; Arteriovenous Malformations; Embolization, Therapeutic; Facial Neoplasms; Hemangioma; Humans; Maxillary Neoplasms; Sodium Morrhuate

Based on the experience of sclerosing therapy for hemangioma, the author puts forward a new method which merges the rescuing, diagnosis and treatment into an organic whole. By injecting 5% sodium morrhuate with iodized oil into the tumor body through diagnostic puncture needle, coagulation, then gradual granulation, fibrosing and mineralization could be expected. Five cases have been followed up for 5-12 years with good results.

Topics: Adolescent; Child; Female; Follow-Up Studies; Hemangioma; Humans; Injections, Intralesional; Iodized Oil; Male; Mandibular Neoplasms; Sclerotherapy; Sodium Morrhuate

The histopathologic aspect of a case of oral soft tissue hemangioma treated with a sclerosing agent is described. Various modes of treatment for hemangioma are discussed.

Topics: Aged; Female; Hemangioma; Humans; Mouth Neoplasms; Sodium Morrhuate

This article reports the case of a patient with a reasonably large maxillary hemangioma involving bone and overlying mucosa. A dramatic shrinkage of the lesion over a 4-week period was noted when sodium morrhuate was used as the sclerosing agent. Four and one half years following therapy, no recurrence of the tumor was noted. Radiographically, the area of involvement had become significantly more dense, with an increase in size and calcification of phleboliths in the area.

Topics: Adult; Fatty Acids; Hemangioma; Humans; Male; Maxillary Neoplasms; Sclerosing Solutions; Sodium Morrhuate

Topics: Adolescent; Fatty Acids; Female; Hemangioma; Humans; Male; Middle Aged; Mouth Neoplasms; Sclerosing Solutions; Sodium Morrhuate